Abstract: The invention relates to an electrolyte solution suitable for use in a zinc-bromine battery, comprising zinc bromide and a mixture of at least two complexing agents selected from the group consisting of 1-R2-2-methyl pyridinium bromide and 1-R3-3-methyl pyridinium bromide salts, wherein each of R2 and R3 is independently an alkyl group having not less than five carbon atoms.

Abstract: The invention provides a process comprising reacting an epoxy novolac resin with monohydroxy aromatic compound, optionally in the presence of a poly-functional agent for linking together the epoxy novolac chains. The polymers thus obtained are modified, solid, novolac epoxy resins which are useful as stabilizers for flame retardants such as polystyrene-block-brominated polybutadiene-block-polystyrene.

Abstract: The invention relates to a method of operating a zinc-bromine battery, especially at a high temperature, comprising adding 1-n-butyl-2-methyl-pyridinium bromide to the electrolyte of said battery, and charging or discharging said cell. Also provided is the use of 1-n-butyl-2-methyl-pyridinium bromide as an additive in a zinc-bromine battery operating at a temperature above 30° C., and an aqueous concentrate with high content of 1-n-butyl-2-methyl-pyridinium bromide.

Abstract: The invention relates to an electrolyte solution suitable for use in a zinc-bromine battery, comprising zinc bromide and a mixture of at least two complexing agents selected from the group consisting of 1-R2-2-methyl pyridinium bromide and 1-R3-3-methyl pyridinium bromide salts, wherein each of R2 and R3 is independently an alkyl group having not less than five carbon atoms.

Abstract: The invention relates to a method of operating a zinc-bromine battery, especially at a high temperature, comprising adding 1-n-butyl-2-methyl-pyridinium bromide to the electrolyte of said battery, and charging or discharging said cell. Also provided is the use of 1-n-butyl-2-methyl-pyridinium bromide as an additive in a zinc-bromine battery operating at a temperature above 30° C., and an aqueous concentrate with high content of 1-n-butyl-2-methyl-pyridinium bromide.

Abstract: The invention relates to the use of at least one 1-alkyl-3-alkyl-pyridinium halide, in particular 1-alkyl-3-methyl-pyridinium bromide, as an additive in bromine-generating electrochemical cells, such as zinc/bromine cells. Processes for preparing 1-alkyl-3-methyl-pyridinium bromide and concentrated aqueous solutions comprising same for use as additives in the aforementioned cells, are also disclosed.

Abstract: The invention relates to the use of nitrogen-containing compounds belonging to the classes of N-alkyl pyridinium halide, N-alkyl-2-alkyl pyridinium halide and 1-alkyl-3-alkyl imidazolium halide, as additives in electrolyte solutions for zinc bromine membraneless flow cells. The invention also provides electrolyte solutions comprising such additives and processes for operating said cells.

Abstract: A process for preparing an aqueous solution of N-ethyl-2-methylpyridinium bromide (2-MEPy), comprising reacting 2-picoline and ethyl bromide in a pressure reactor at a temperature above the melting point of the reaction mixture, combining the reaction product with water, wherein said reaction product consists essentially of 2-MEPy in a liquid form, and recovering an aqueous solution of 2-MEPy.

Abstract: The invention relates to the use of at least one 1-alkyl-3-alkyl-pyridinium halide, in particular 1-alkyl-3-methyl-pyridinium bromide, as an additive in bromine-generating electrochemical cells, such as zinc/bromine cells. Processes for preparing 1-alkyl-3-methyl-pyridinium bromide and concentrated aqueous solutions comprising same for use as additives in the aforementioned cells, are also disclosed.

Abstract: The invention relates to the use of nitrogen-containing compounds belonging to the classes of N-alkyl pyridinium halide, N-alkyl-2-alkyl pyridinium halide and 1-alkyl-3-alkyl imidazolium halide, as additives in electrolyte solutions for zinc bromine membraneless flow cells. The invention also provides electrolyte solutions comprising such additives and processes for operating said cells.

Abstract: A method for generating molecular bromine in bromide-containing electrolyte solution suitable for use in a metal bromine cell, involves chemically oxidizing bromide (Br?) in the electrolyte solution in an acidic environment, to produce the molecular bromine.

Abstract: A process for preparing an aqueous solution of N-ethyl-2-methylpyridinium bromide (2-MEPy), comprising reacting 2-picoline and ethyl bromide in a pressure reactor at a temperature above the melting point of the reaction mixture, combining the reaction product with water, wherein said reaction product consists essentially of 2-MEPy in a liquid form, and recovering an aqueous solution of 2-MEPy.

Abstract: The present invention provides new tyrphostin derivatives acting as protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, and/or which directly or indirectly affect proteins in the PTK-mediated signal transduction pathway, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Abstract: The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Abstract: A method for generating molecular bromine in bromide-containing electrolyte solution suitable for use in a metal bromine cell, involves chemically oxidizing bromide (Br?) in the electrolyte solution in an acidic environment, to produce the molecular bromine.

Abstract: The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Abstract: A process for preparing a polybrominated product such as decabromodiphenyl ether and decabromodiphenyl ethane, which comprises brominating a reduced particle size precursor of said polybrominated product in an organic solvent or in bromine as a solvent, wherein the bromination is carried out either concurrently with or subsequent to said particle size reduction, forming the polybrominated product and separating the same from the reaction mixture.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.